Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01157364

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

An Open-label (Stage 1) and Randomized (Stage 2), 24 Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension

Sponsor: Allergan

Conditions Ocular Hypertension Open-Angle Glaucoma

Interventions bimatoprost 0.03% bimatoprost 10 µg generation 1 bimatoprost 10 µg generation 2 bimatoprost 15 µg generation 1 bimatoprost 15 µg generation 2 bimatoprost 20 µg generation 2 bimatoprost 6 µg generation 2

Updated 9 times since 2017 Last updated: Mar 27, 2020 Started: Sep 23, 2010 Primary completion: Jul 27, 2016 Completion: Aug 9, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Ocular Hypertension and Open-Angle Glaucoma and is currently completed. Allergan leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Jun 2018 — Apr 2020 [monthly]

Completed PHASE1_PHASE2
Feb 2018 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Feb 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Artesia, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Boisbriand, Canada , Boston, United States , Bradenton, United States , Calgary, Canada , Charlotte, United States , Chatham, Canada and 44 more locations